---
title: "Nordicus Partners Corp SEC 10-Q Report"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275939847.md"
description: "Nordicus Partners Corp has released its Form 10-Q report for Q3, showing a revenue of $0, down from $2,500 last year. The company reported a loss from operations of $(1,122,172), an improvement from $(1,265,310) previously. Net loss decreased to $(1,247,524) from $(1,545,311), with a net loss per share of $(0.07). The company focuses on Nordic life sciences, managing three preclinical biotech firms. Future plans include advancing clinical trials and potential exits through sales or IPOs."
datetime: "2026-02-13T19:51:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275939847.md)
  - [en](https://longbridge.com/en/news/275939847.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275939847.md)
---

# Nordicus Partners Corp SEC 10-Q Report

Nordicus Partners Corp, a business accelerator and holding company for Nordic life sciences companies, has released its Form 10-Q report for the third quarter. The report provides a comprehensive overview of the company's financial performance and operational developments, reflecting its strategic focus on advancing Nordic innovation in the American market.

**Financial Highlights**

**Revenue**: $0, reflecting a decrease from $2,500 in the same period last year, indicating a lack of sales activity during the reporting period.

**Loss from Operations**: $(1,122,172), compared to $(1,265,310) in the prior year, showing a slight improvement in operational efficiency.

**Net Loss**: $(1,247,524), compared to $(1,545,311) in the previous year, indicating a reduction in overall losses.

**Net Loss Per Share**: $(0.07), compared to $(0.13) in the prior year, reflecting a decrease in loss per share due to an increase in the number of shares outstanding.

**Business Highlights**

**Organizational History**: Nordicus Partners Corporation, originally founded in 1993, has undergone several transformations, including a name change to Nordicus Partners Corporation in May 2023. The company has shifted its focus to becoming a business accelerator and holding company for Nordic life sciences companies aiming to enter the American market.

**Portfolio Companies**: Nordicus currently manages three preclinical biotechnology companies: Orocidin A/S, Bio-Convert A/S, and NoviThera ApS. These companies are focused on developing innovative treatments for aggressive periodontitis, oral leukoplakia, and psoriasis, respectively.

**Orocidin A/S Developments**: Orocidin has completed a 14-day toxicology study in hamsters and a test of effectiveness in a Beagle Dog Study, showing promising results for its lead product, QR-01, in treating periodontitis.

**Bio-Convert A/S Developments**: Bio-Convert received positive feedback from the Danish Medicines Agency regarding its lead candidate, QR-02, for treating oral leukoplakia, paving the way for a First in Human trial.

**NoviThera ApS Formation**: In October 2025, Nordicus formed NoviThera to develop a novel Monoclonal antibody for psoriasis treatment, with intellectual property contributed by Alteral Therapeutics.

**Future Outlook**: Nordicus aims to advance its portfolio companies through Phase I clinical trials, with potential exit strategies including sales, mergers, strategic partnerships, or IPOs. The company is focused on leveraging Nordic innovation and U.S. operational expertise to create value in high-growth markets with unmet medical needs.

SEC Filing: Nordicus Partners Corp \[ NORD \] - 10-Q - Feb. 13, 2026

### Related Stocks

- [NORD.US](https://longbridge.com/en/quote/NORD.US.md)

## Related News & Research

- [1 surprising way Oklo could benefit from the looming SpaceX IPO](https://longbridge.com/en/news/286652457.md)
- [Cerebras IPO Euphoria Sends CBRS Stock Into Rare Air](https://longbridge.com/en/news/286763495.md)
- [SpaceX IPO: 3 scenarios for what a $5,000 investment could be worth by 2030](https://longbridge.com/en/news/286642151.md)
- [Blackstone Has a New Data Center REIT. Its BXDC IPO Might Be a Little Too Late.](https://longbridge.com/en/news/286430885.md)
- [SEC announces new rules to make IPOs great again](https://longbridge.com/en/news/286959614.md)